Inhibikase Therapeutics initiated a global pivotal Phase 3 clinical trial called IMPROVE-PAH for its drug IKT-001 targeting Pulmonary Arterial Hypertension (PAH), following FDA approval and site activations in the US. The adaptive trial will enroll around 486 patients worldwide with endpoints measuring pulmonary vascular resistance and walking distance. The company raised $115 million in a public offering in 2025 and ended the year with $178.8 million in cash. Despite a net loss of $48.3 million in 2025, Inhibikase is advancing regulatory approvals in over 20 countries and aims to accelerate trial timelines through the EU's FAST-EU initiative.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
Alphamin Resources delivers strong free cash flow from its high-grade Bisie tin mine, maintaining consistent output of 20,000 tonnes per annum. Despite operational risks in the Democratic Republic of Congo, the company trades at a significant valuati...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
